Aspen Aerogels, Inc. (NYSE:ASPN) Receives $29.70 Consensus Target Price from Brokerages

Aspen Aerogels, Inc. (NYSE:ASPN) has been assigned a consensus rating of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat reports. Nine analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $29.70.

Several equities analysts recently issued reports on the company. Benchmark restated a “buy” rating and set a $14.00 price target on shares of Aspen Aerogels in a research report on Thursday, August 8th. TD Cowen raised their target price on shares of Aspen Aerogels from $36.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, August 20th. Roth Mkm reiterated a “buy” rating and set a $36.00 price target on shares of Aspen Aerogels in a report on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Aspen Aerogels in a report on Wednesday. Finally, Barclays began coverage on shares of Aspen Aerogels in a research report on Tuesday, August 6th. They issued an “overweight” rating and a $27.00 price objective on the stock.

Aspen Aerogels Stock Up 13.2 %

Shares of NYSE:ASPN opened at $25.41 on Friday. The firm has a market capitalization of $1.94 billion, a PE ratio of -57.75 and a beta of 2.16. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.82 and a current ratio of 3.46. Aspen Aerogels has a 52-week low of $6.62 and a 52-week high of $33.15. The firm has a fifty day moving average of $25.98 and a 200 day moving average of $24.33.

Aspen Aerogels (NYSE:ASPN) last released its earnings results on Wednesday, August 7th. The construction company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16. The company had revenue of $117.80 million during the quarter, compared to the consensus estimate of $101.99 million. Aspen Aerogels had a return on equity of 0.74% and a net margin of 0.39%. Aspen Aerogels’s quarterly revenue was up 144.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.22) EPS. As a group, research analysts anticipate that Aspen Aerogels will post 0.21 EPS for the current fiscal year.

Insider Transactions at Aspen Aerogels

In related news, CEO Donald R. Young sold 63,355 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $30.03, for a total value of $1,902,550.65. Following the transaction, the chief executive officer now directly owns 483,640 shares of the company’s stock, valued at approximately $14,523,709.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Aspen Aerogels news, CEO Donald R. Young sold 63,355 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the transaction, the chief executive officer now owns 483,640 shares in the company, valued at approximately $14,523,709.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Ricardo C. Rodriguez sold 32,465 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $30.14, for a total transaction of $978,495.10. Following the sale, the chief financial officer now directly owns 20,790 shares in the company, valued at approximately $626,610.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Banque Cantonale Vaudoise grew its position in shares of Aspen Aerogels by 37.5% during the 1st quarter. Banque Cantonale Vaudoise now owns 4,593 shares of the construction company’s stock valued at $81,000 after acquiring an additional 1,252 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Aspen Aerogels by 10.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,310 shares of the construction company’s stock valued at $341,000 after purchasing an additional 1,339 shares during the period. nVerses Capital LLC increased its position in Aspen Aerogels by 45.0% in the third quarter. nVerses Capital LLC now owns 5,800 shares of the construction company’s stock worth $161,000 after buying an additional 1,800 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Aspen Aerogels by 15.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,580 shares of the construction company’s stock worth $257,000 after buying an additional 1,938 shares during the period. Finally, Point72 Hong Kong Ltd purchased a new position in shares of Aspen Aerogels during the 2nd quarter valued at about $84,000. Institutional investors own 97.64% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.